|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||25.06 - 25.06|
|52 Week Range||17.50 - 29.74|
|Beta (5Y Monthly)||0.30|
|PE Ratio (TTM)||32.04|
|Forward Dividend & Yield||0.16 (0.59%)|
|Ex-Dividend Date||May 12, 2021|
|1y Target Est||N/A|
Resmed (NYSE: RMD), Walgreens Boots Alliance (NASDAQ: WBA) and AbbVie (NYSE: ABBV) are profitable companies that have clear paths to future revenue growth. ResMed is already an industry leader in sleep apnea therapies, an area that's expected to grow as our population ages. Walgreens Boots Alliance is jumping onto the trend toward value-oriented healthcare services, and AbbVie's huge stable of drugs and pipeline give it a diversity that protects its long-term outlook.
Brett Sandercock, Chief Financial Officer at Resmed (NYSE:RMD), made a large buy and sell of company shares on October 11, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that Brett Sandercock exercised options to purchase 2,500 Resmed shares at a price of $57.76 per share for a total of $144,400 on October 11. They then sold their shares on the same day in the open market. They sold at a price of $253.37 to raise a total of $
After all, Wall Street doesn't sell a stock unless it believes there is a better place for the money -- at least in the short term. Knowing you plan to hold for years, and not having anyone but yourself to answer to, can focus your analysis on the company and its prospects. As company reputations go, Johnson & Johnson offers one of the strangest juxtapositions.